Clinical Trial Update: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) [Phase 2]

View source ↗

Summary

Phase 2 study of RC48 plus sintilimab and S-1 as first-line therapy for advanced gastric cancer, including HER2-positive, metastatic, and unresectable cases; tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Unresectable Gastric Cancer

Drugs mentioned

• RC48 (disitamab vedotin) (disitamab vedotin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: HER2-positive Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Status: RECRUITING